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Exonic enhancers (eExons) are coding exons that
also function as enhancers of the gene in which
they reside or (a) nearby gene(s). Mutations that
affect the enhancer activity of these eExons have
been associated with human disease. Therefore,
eExon mutations should be taken into account in
exome and genome sequencing projects, not only
because of the ability of these mutations to modify
the encoded proteins but also because of their
effects on enhancer activity.an unbiased manner [4, 7].Exonic enhancers
Exonic enhancers (eExons) are protein-coding exons
that have an additional function as enhancers — gene
regulatory elements that instruct promoters as to when,
where and at what levels they should be active. En-
hancers are activated by the binding of transcription
factors and cofactors, which subsequently leads to the
activation of their target promoters, either through
looping interactions between the enhancer and the pro-
moter or via other mechanisms such as tracking or
chromatin modifications [1]. eExons have been shown
to regulate the gene in which they reside [2, 3] or even
(a) neighboring gene(s) [4].
eExons were discovered by carrying out functional
gene regulatory assays. In an enhancer assay the poten-
tial enhancer sequence — in this case the coding exon
— is placed in front of a minimal promoter (a promoter
that should only drive expression if it has an enhancer in
front of it) followed by a reporter gene, and checked for
its ability to turn on the reporter gene. Experiments in
which these assays were used showed that eExons were
able to drive expression of a reporter gene (see [2] for anCorrespondence: nadav.ahituv@ucsf.edu
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tive genomics [3, 5, 6]. For example, in a comparison of 29
mammalian genomes, human protein-coding sequences
were scanned for regions that have low synonymous
substitution rates, which could suggest that they have
additional functions, such as being enhancers [6]. This
analysis showed that over a quarter of all human
protein-coding genes contain these synonymous con-
straint elements. eExons can also be detected using
chromatin immunoprecipitation sequencing (ChIP-seq),
DNase I hypersensitive site sequencing (DNase-seq) or
other genomic technologies that can identify enhancers in
Mutations in eExons could lead to human disease by
altering their enhancer activity. eExons 15 and 17 of the
dynein cytoplasmic 1 intermediate chain 1 (DYNC1I1)
gene are examples of eExons that have been associated
with human disease (Fig. 1a). These eExons were shown
to be functional enhancers in the developing limb using
mouse transgenic enhancer assays. They were also shown
to interact with the promoters of distal-less homeobox 5
(DLX5) and distal-less homeobox 6 (DLX6) in the devel-
oping limb [4]. These promoters reside ~900 kb away
from DYNC1I1. DLX5 and DLX6 are important for limb
development and have been associated with split hand
and foot malformation (SHFM) in humans [4]. Analysis of
patients with SHFM found several chromosomal aber-
rations that overlap DYNC1I1 exons 15 and 17 (Fig. 1a)
[4, 8, 9], which suggests that alterations in these exons
could lead to the SHFM phenotype.Coding mutations should be carefully examined
Genomic analyses have also shown that eExons can be
quite common in the genome, making up an estimated
7 % of the putative enhancers detected using ChIP-seq
[4]. Furthermore, ~15 % of human codons are thought
to have sites that are bound by transcription factors
(termed duons) on the basis of footprinting analyses of
DNase-seq data [7]. Despite being common, the conse-
quences of nucleotide changes on the enhancer functiontributed under the terms of the Creative Commons Attribution 4.0 International
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Fig. 1 DYNC1I1 exonic enhancers (eExons) regulate DLX5 and DLX6.
a The DYNC1I1-DLX5/6 locus has two known eExons, DYNC1I1
exons 15 and 17 (colored in blue), that are functional limb
enhancers and were shown to interact with DLX5 and DLX6 [4]. A
106 kb deletion (red line) that contains these eExons was found in
an individual with split hand and foot malformation (SHFM) [10]. b A
fictional example of a mutation in an eExon that could be overlooked
in exome or genome sequencing studies. The chromatogram shows a
synonymous mutation in an eExon that could leave the protein
sequence unchanged but could affect a transcription factor binding
site (logo plot below) leading to changes in the enhancer function of
this eExon. DLX5 Distal-less homeobox 5, DLX6 Distal-less homeobox 6,
DYNC1I1 Dynein cytoplasmic 1 intermediate chain 1
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analyses. Massively parallel reporter assays have shown
that the essential functional enhancer sequence of eExons
is intertwined with the protein-coding sequence, with both
nonsynonymous, synonymous and splice junction muta-
tions having similar deleterious effects on enhancer activ-
ity [10]. The transcription factor binding sites were found
to be the main constrictive force governing the enhancer
function of eExons in this assay. Therefore, a mutation in
an eExon, even a synonymous mutation or a mutation in
a splice junction, could alter the enhancer activity of this
regulatory element and have phenotypic consequences in-
dependent of alterations to the protein sequence.
Numerous exome sequencing, whole-genome sequen-
cing and copy number variant (CNV) studies that aim to
identify mutations that cause disease or other phenotypic
changes have been carried out or are in progress. More
than 17 % of single nucleotide variants (SNVs) in coding
sequences that overlap a potential functional transcription
factor binding site are estimated to alter the site itself [7].
In addition, 13.5 % of coding SNVs that have been asso-
ciated with disease through genome-wide association
studies overlap transcription factor binding sites; 12 %
of these SNVs are synonymous and 88 % are nonsynon-
ymous mutations [7]. However, computational analyses
in exome or genome sequencing studies are primarily
focused on detecting protein-modifying mutations in
coding exons and do not specifically consider muta-
tions in eExons that could alter enhancer activity. There-
fore, several disease-causing mutations could have been
overlooked. For example, a coding mutation in the limb-
related DYNC1I1 eExons in a patient with SHFM wouldprobably be considered non-deleterious and ignored in
an exome or genome sequencing study (also due to
DYNC1I1 not having a known role in limb develop-
ment), unless these sequences were known to function
as eExons (Fig. 1b).
Fixing the problem: how to take eExons into
account in mutation analyses
We need to be more conscious of eExons and take them
into account when analyzing CNVs and short-sequence
variants in exome or genome sequencing data. However,
this is not an easy task. Enhancers tend to be cell-type-
specific and so eExons could be active only in a specific
cell type or tissue, which would make their detection
complex. Nevertheless, there are numerous genomic
datasets (such as ENCODE or the Roadmap Epige-
nomics datasets) in which enhancers for various cell
types or tissues are annotated, and these datasets will
keep on growing. A combined database that provides a
list of cell-type-specific or tissue-specific eExons would
greatly assist researchers and could be integrated in
computational protocols or programs that carry out
mutation analyses. The use of programs that predict the
effect of regulatory variants on coding sequences, or
tools that treat sequences in an unbiased manner regard-
ing their location (that is, in which coding and noncod-
ing mutations are treated similarly), could and should be
used to identify changes in eExons that adversely affect
their regulatory function.
Another limitation is that an eExon could regulate a
nearby gene and not the gene in which it resides, as is
the case for the DYNC1I1 eExons (Fig. 1). Researchers,
despite being aware of the presence of eExons, might ig-
nore a variant in a gene that does not have a known
function or that does not fit with the phenotype being
analyzed. The use of patient gene expression data, such
as RNA sequencing (RNA-seq) data, could aid in the
identification of a regulatory problem and the gene that
is differentially regulated as a consequence. In addition,
the use of chromosome conformation datasets [obtained
through Hi-C or chromatin interaction analysis by paired-
end tag sequencing (ChIA-PET)], when available for the
specific cell type or tissue being studied, could assist in
assigning target genes to these eExons and these datasets
should be taken into account, as should be done when
analyzing noncoding enhancers.
In summary, we have not been and are not currently
paying sufficient attention in genome and exome se-
quencing projects to the effects of coding mutations on
enhancer activity and other functional elements that
could reside in exons. Other than enhancer activity that
could reside in exons, these functional elements could
include splicing enhancers, RNA secondary structures,
microRNA target sites and even dual-coding genes. To
Ahituv Genome Medicine  (2016) 8:14 Page 3 of 3conclude, eExons need to be kept in mind when carrying
out mutation analyses, in particular for unsolved cases.
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